Trial Profile
Abatacept Reversing Subclinical Inflammation as Measured by MRI in ACPA Positive Arthralgia (ARIAA)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Dec 2022
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Inflammation; Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms ARIAA
- 14 Nov 2022 Results presented at the ACR Convergence 2022
- 04 Jun 2022 Results assessing the effect of treatment of abatacept, as compared to placebo, delays the onset of RA in ACPA positive individuals with a high risk to develop RA presented at the 23rd Annual Congress of the European League Against Rheumatism
- 09 Mar 2020 Status changed from recruiting to completed.